Joshua Levine Sells 6,604 Shares of Accuray Incorporated (ARAY) Stock

Accuray Incorporated (NASDAQ:ARAY) CEO Joshua Levine sold 6,604 shares of Accuray stock in a transaction that occurred on Tuesday, April 2nd. The shares were sold at an average price of $4.54, for a total value of $29,982.16. Following the sale, the chief executive officer now directly owns 1,033,593 shares in the company, valued at $4,692,512.22. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link.

Shares of ARAY traded up $0.10 during mid-day trading on Friday, reaching $4.35. The company had a trading volume of 567,043 shares, compared to its average volume of 879,263. The company has a quick ratio of 1.00, a current ratio of 1.71 and a debt-to-equity ratio of 2.97. Accuray Incorporated has a 52 week low of $3.16 and a 52 week high of $5.40. The stock has a market cap of $379.64 million, a P/E ratio of -15.54 and a beta of 2.07.

Accuray (NASDAQ:ARAY) last issued its quarterly earnings results on Tuesday, April 23rd. The medical equipment provider reported ($0.01) EPS for the quarter, topping analysts’ consensus estimates of ($0.04) by $0.03. Accuray had a negative return on equity of 25.96% and a negative net margin of 3.85%. The firm had revenue of $103.22 million for the quarter, compared to analysts’ expectations of $104.02 million. On average, equities analysts anticipate that Accuray Incorporated will post -0.16 EPS for the current year.

A number of hedge funds and other institutional investors have recently made changes to their positions in the stock. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. raised its holdings in Accuray by 10.9% in the 1st quarter. Mitsubishi UFJ Kokusai Asset Management Co. Ltd. now owns 44,754 shares of the medical equipment provider’s stock worth $213,000 after acquiring an additional 4,392 shares during the last quarter. Bank of Montreal Can raised its holdings in Accuray by 162.0% in the 1st quarter. Bank of Montreal Can now owns 32,118 shares of the medical equipment provider’s stock worth $153,000 after acquiring an additional 19,858 shares during the last quarter. Assenagon Asset Management S.A. raised its holdings in Accuray by 79.7% in the 1st quarter. Assenagon Asset Management S.A. now owns 930,916 shares of the medical equipment provider’s stock worth $4,440,000 after acquiring an additional 412,925 shares during the last quarter. BNP Paribas Arbitrage SA raised its holdings in Accuray by 1,515.8% in the 1st quarter. BNP Paribas Arbitrage SA now owns 19,099 shares of the medical equipment provider’s stock worth $91,000 after acquiring an additional 17,917 shares during the last quarter. Finally, Bailard Inc. purchased a new position in Accuray in the 1st quarter worth approximately $102,000. Institutional investors own 80.19% of the company’s stock.

Several analysts have weighed in on the company. BTIG Research reaffirmed a “hold” rating on shares of Accuray in a research report on Wednesday. BidaskClub raised Accuray from a “sell” rating to a “hold” rating in a research report on Wednesday. Finally, Zacks Investment Research cut Accuray from a “buy” rating to a “hold” rating in a research report on Friday, February 15th. Five analysts have rated the stock with a hold rating and one has assigned a buy rating to the company’s stock. The stock has an average rating of “Hold” and a consensus target price of $5.13.

TRADEMARK VIOLATION WARNING: “Joshua Levine Sells 6,604 Shares of Accuray Incorporated (ARAY) Stock” was first posted by Baseball Daily News and is the sole property of of Baseball Daily News. If you are viewing this piece of content on another domain, it was copied illegally and reposted in violation of United States and international trademark & copyright laws. The correct version of this piece of content can be accessed at https://www.baseballdailydigest.com/news/2019/04/27/accuray-incorporated-aray-ceo-joshua-levine-sells-6604-shares.html.

About Accuray

Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body.

Recommended Story: Purposes and Functions of the Federal Reserve

Insider Buying and Selling by Quarter for Accuray (NASDAQ:ARAY)

Receive News & Ratings for Accuray Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Accuray and related companies with MarketBeat.com's FREE daily email newsletter.